Martin Laboratories

Martin Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for orphan diseases, with a primary focus on respiratory and infectious conditions. The company's lead candidate, MP-101, is a novel formulation of clofazimine designed to treat nontuberculous mycobacteria (NTM) lung disease while minimizing the systemic side effects typically associated with the drug. By leveraging advanced drug delivery technologies, Martin Pharmaceuticals aims to provide more effective and tolerable treatment options for patients with chronic pulmonary infections. The company is headquartered in Richmond, Virginia, and continues to advance its pipeline through clinical development and strategic collaborations.